Search Results

You are looking at 41 - 50 of 72 items for :

  • Refine by Access: All x
Clear All
Full access

Chloe E. Atreya, Claire Greene, Ryan M. McWhirter, Nabia S. Ikram, I. Elaine Allen, Katherine Van Loon, Alan P. Venook, Benjamin M. Yeh, and Spencer C. Behr

patients with BRAF -mutated tumors was approximately 1 year. 21 , 22 The explanation for the poor survival of patients with BRAF -mutated mCRC is incompletely understood but may relate to inherent chemoresistance, aggressive disease biology and kinetics

Full access

Todd L. Demmy, Lin Gu, Jack E. Burkhalter, Eric M. Toloza, Thomas A. D'Amico, Susan Sutherland, Xiaofei Wang, Laura Archer, Linda J. Veit, Leslie Kohman, and the Cancer and Leukemia Group B

M . Malignant pleural effusion and talc pleurodesis. Experimental model regarding early kinetics of talc particle dissemination in the chest after experimental talc pleurodesis . J BUON 2009 ; 14 : 419 – 423 . 16 Warren W . Talc

Full access

Olga Frankfurt and Martin S. Tallman

acute promyelocytic leukemia without cytarabine . J Clin Oncol 1997 ; 15 : 483 – 490 . 90. Burnett AK Grimwade D Solomon E . Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic

Full access

Holly Dushkin and Massimo Cristofanilli

– 2565 . 9. Gruber G Ciriolo M Altermatt HJ . Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer . Int J Cancer 2004 ; 109 : 144 – 148 . 10. Paradiso A Tommasi S Brandi M . Cell kinetics and hormonal

Full access

Kavea Panneerselvam, Rajan N. Amin, Dongguang Wei, Dongfeng Tan, Phillip J. Lum, Hao Chi Zhang, David M. Richards, Mehmet Altan, Petros Grivas, John A. Thompson, Anusha S. Thomas, and Yinghong Wang

JS , Kähler KC , Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab . J Clin Oncol 2012 ; 30 : 2691 – 2697 . 10.1200/JCO.2012.41.6750 22614989 8. Michot JM , Bigenwald C , Champiat S

Full access

Timothy Gilligan, Daniel W. Lin, Rahul Aggarwal, David Chism, Nicholas Cost, Ithaar H. Derweesh, Hamid Emamekhoo, Darren R. Feldman, Daniel M. Geynisman, Steven L. Hancock, Chad LaGrange, Ellis G. Levine, Thomas Longo, Will Lowrance, Bradley McGregor, Paul Monk, Joel Picus, Phillip Pierorazio, Soroush Rais-Bahrami, Philip Saylor, Kanishka Sircar, David C. Smith, Katherine Tzou, Daniel Vaena, David Vaughn, Kosj Yamoah, Jonathan Yamzon, Alyse Johnson-Chilla, Jennifer Keller, and Lenora A. Pluchino

before orchiectomy, it is important to obtain the half-life kinetics of the tumor markers after orchiectomy if the markers are declining, because a slower-than-expected decline often indicates the presence of metastatic disease. The NCCN Panel emphasizes

Full access

Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Stefan K. Barta, Uma Borate, Michael W. Boyer, Patrick W. Burke, Ryan Cassaday, Januario E. Castro, Peter F. Coccia, Steven E. Coutre, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Olga Frankfurt, John P. Greer, Robert A. Johnson, Hagop M. Kantarjian, Rebecca B. Klisovic, Gary Kupfer, Mark Litzow, Arthur Liu, Arati V. Rao, Bijal Shah, Geoffrey L. Uy, Eunice S. Wang, Andrew D. Zelenetz, Kristina Gregory, and Courtney Smith

based on early MRD measurements. Large trials are warranted to address these possibilities, although serial MRD measurements may likely be needed to monitor leukemic cell kinetics during the long course of treatment. MRD Assessment in Adult ALL

Full access

John A. Thompson, Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew Frigault, Brianna Hoffner, Christopher J. Hoimes, Mario Lacouture, Frederick Locke, Matthew Lunning, Nisha A. Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan Oluwole, Sandip P. Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Momen Wahidi, Yinghong Wang, Alyse Johnson-Chilla, and Jillian L. Scavone

did not appear to alter the kinetics of tumor response or durability. 30 Another analysis of pooled data from these trials showed similar survival outcomes between patients with GI irAEs who received corticosteroid therapy with or without infliximab

Full access

Alejandro Garcia-Horton and Jeffrey H. Lipton

inhibitors . J Clin Oncol 2012 ; 30 : 232 – 238 . https://doi.org/10.1200/JCO.2011.38.6565 22067393 10.1200/JCO.2011.38.6565 38. Shanmuganathan N , Branford S , Pagani I , . Early BCR-ABL1 kinetics are predictive of subsequent achievement of

Full access

Melanoma, Version 2.2013

Featured Updates to the NCCN Guidelines

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Dominick DiMaio, Martin D. Fleming, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Maria Ho

whom steroid therapy was not required. 23 Overall response rates after administration of ipilimumab range from 10% to 20% and are often slow to manifest, sometimes occurring 6 months or more after initiation of therapy. The kinetics of response is